No Data
Wells Fargo Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $250
William Blair Maintains Biogen(BIIB.US) With Buy Rating
Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky
Denali, Biogen Halt Parkinson's Trial After Efficacy Failure
Biogen And Denali Discontinue BIIB122 Development In Idiopathic Parkinson's Disease After Phase 2b LUMA Trial Misses Primary And Secondary Endpoints
Express News | Biogen - Data From Beacon Study Anticipated in First Half of 2027